All the news Showing 8 of 8 articles from: AASLD 2021Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis delta Bulevirtide for hepatitis D proves effective in real-world studies Liz Highleyman / 25 January 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load and improved liver enzyme levels in real-world studies in France and Austria, according to findings presented ... Hepatocellular carcinoma (HCC) Some people remain at risk for liver cancer despite hepatitis C treatment Liz Highleyman / 22 December 2021 Some people with liver cirrhosis remain at risk for developing hepatocellular carcinoma (HCC) even after hepatitis C treatment, according to study results presented at The Liver Meeting. Not achieving a cure was the biggest ... Treatment for previous non-responders & relapsers Three-drug regimen plus ribavirin cures the hardest-to-treat hepatitis C patients Keith Alcorn / 08 December 2021 People who have experienced failure of multiple courses of direct-acting antiviral treatment can be cured of hepatitis C with a combination of three direct-acting antivirals plus ribavirin, a review of heavily treatment-experienced patients ... Coronavirus COVID-19 vaccine protection is ‘lower and slower’ in people with cirrhosis Keith Alcorn / 22 November 2021 People with cirrhosis of the liver may take longer to achieve protection from SARS-CoV-2 and severe COVID-19 after vaccination, according to large studies in the United States and Chile, presented earlier this month ... Coronavirus People with liver cirrhosis have weaker responses to the Pfizer and Moderna SARS-CoV-2 vaccines Keith Alcorn / 16 November 2021 People with cirrhosis of the liver had delayed and suboptimal responses to the Pfizer or Moderna SARS-CoV-2 vaccines compared to healthy adults, an Italian study has found. People with decompensated cirrhosis had significantly ... Coronavirus Treatment for hepatitis B and C fell in 2020 due to COVID-19, global survey finds Keith Alcorn / 16 November 2021 Viral hepatitis tests and treatment declined significantly during 2020 as a consequence of the COVID-19 pandemic, a survey of 31 liver centres on five continents has shown. The decline in testing and ... Hepatitis C elimination Hepatitis C elimination: less than 25% of people with hepatitis C diagnosed globally Keith Alcorn / 15 November 2021 The global prevalence of hepatitis C has declined since 2015, partly due to scale-up of direct-acting antiviral treatment, but fewer than one in four people with hepatitis C has been diagnosed, ... Hepatitis C elimination Hepatitis C treatment in US declined from 2015 to 2020 Liz Highleyman / 14 November 2021 From a height of more than 164,000 in 2015, the number of people treated with direct-acting antiviral (DAA) therapy for hepatitis C has steadily declined, reaching a low point during the COVID-19 pandemic, ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive